Sarepta Sinks On Mixed DMD Gene Therapy Study
Blames 'Bad Luck In Randomization Process'
Executive Summary
Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.
You may also be interested in...
Five (Non-COVID) Clinical Trial Misses Of 2021
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy
CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.
Five (Non-COVID) Clinical Trial Misses Of 2021
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.